Other consortia approaches like the new European and Developing Country Clinical Trials Program (EDCTP) are also needed and require funding well in excess of its current budget of $400 million for 5 years (2003-2008) for HIV, TB, and malaria. With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information exchange, the WGND conducts an annual survey of the global TB drugs pipeline. Join our mailing list and receive the latest news from TB Alliance. Tuberculosis drugs target various aspects of Mycobacterium tuberculosis biology, including inhibition of cell wall synthesis, protein synthesis, or nucleic acid synthesis.
Inappropriate management can have life-threatening results. Some newer fluoroquinolones are effective against non-dividing bacteria as well; they do not have cross-resistance to other classes of TB drugs. The sterilizing effects of M and G have the potential to reduce time to culture-conversion, thereby reducing the transmission and potential for relapse. Harries A- a. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. TBTC 17th Semi-Annual Group Meeting, San Diego, CA, 20 May 2005.Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Though in its recent trials the TBTC has added well-performing and highly productive international sites in Brazil, South Africa, and Uganda, TBTC is mainly centered in North America, where TB case rates are still falling.
Other consortia approaches like the new European and Developing Country Clinical Trials Program (EDCTP) are also needed and require funding well in excess of its current budget of $400 million for 5 years (2003-2008) for HIV, TB, and malaria. With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information exchange, the WGND conducts an annual survey of the global TB drugs pipeline. Join our mailing list and receive the latest news from TB Alliance. Tuberculosis drugs target various aspects of Mycobacterium tuberculosis biology, including inhibition of cell wall synthesis, protein synthesis, or nucleic acid synthesis.
Inappropriate management can have life-threatening results. Some newer fluoroquinolones are effective against non-dividing bacteria as well; they do not have cross-resistance to other classes of TB drugs. The sterilizing effects of M and G have the potential to reduce time to culture-conversion, thereby reducing the transmission and potential for relapse. Harries A- a. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. TBTC 17th Semi-Annual Group Meeting, San Diego, CA, 20 May 2005.Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Though in its recent trials the TBTC has added well-performing and highly productive international sites in Brazil, South Africa, and Uganda, TBTC is mainly centered in North America, where TB case rates are still falling.
Other consortia approaches like the new European and Developing Country Clinical Trials Program (EDCTP) are also needed and require funding well in excess of its current budget of $400 million for 5 years (2003-2008) for HIV, TB, and malaria. With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information exchange, the WGND conducts an annual survey of the global TB drugs pipeline. Join our mailing list and receive the latest news from TB Alliance. Tuberculosis drugs target various aspects of Mycobacterium tuberculosis biology, including inhibition of cell wall synthesis, protein synthesis, or nucleic acid synthesis.
Inappropriate management can have life-threatening results. Some newer fluoroquinolones are effective against non-dividing bacteria as well; they do not have cross-resistance to other classes of TB drugs. The sterilizing effects of M and G have the potential to reduce time to culture-conversion, thereby reducing the transmission and potential for relapse. Harries A- a. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. TBTC 17th Semi-Annual Group Meeting, San Diego, CA, 20 May 2005.Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Though in its recent trials the TBTC has added well-performing and highly productive international sites in Brazil, South Africa, and Uganda, TBTC is mainly centered in North America, where TB case rates are still falling.
New trial designs need to be devised as well as rapid, well-designed, well-controlled studies for these drugs to make a difference in reducing the world's TB and TB/HIV epidemics in the near future. ȳڵkׂ]`�`���Xdw��ծ� �L�ލ̃q�|ki�,�;��Ǐ@D�� Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. First Chiron Corporation acquired the compound and then the Global Alliance For TB Drug Development obtained worldwide rights to it and its derivatives from Chiron with Chiron's commitment to make the drug available for TB without royalty in countries where TB is endemic. This family includes ciprofloxacin and a variety of related compounds, two of which are in the current TB pipeline. H�b```f``ac`����cc`a�X��,�'�y���k��Ư���*[,8�6)y;5�9�X"Q��˴�{'��,�+3��6��h�&R����F�`j��E�v�"� +��[���>4n�
Other consortia approaches like the new European and Developing Country Clinical Trials Program (EDCTP) are also needed and require funding well in excess of its current budget of $400 million for 5 years (2003-2008) for HIV, TB, and malaria. With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information exchange, the WGND conducts an annual survey of the global TB drugs pipeline. Join our mailing list and receive the latest news from TB Alliance. Tuberculosis drugs target various aspects of Mycobacterium tuberculosis biology, including inhibition of cell wall synthesis, protein synthesis, or nucleic acid synthesis.
Inappropriate management can have life-threatening results. Some newer fluoroquinolones are effective against non-dividing bacteria as well; they do not have cross-resistance to other classes of TB drugs. The sterilizing effects of M and G have the potential to reduce time to culture-conversion, thereby reducing the transmission and potential for relapse. Harries A- a. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. TBTC 17th Semi-Annual Group Meeting, San Diego, CA, 20 May 2005.Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Though in its recent trials the TBTC has added well-performing and highly productive international sites in Brazil, South Africa, and Uganda, TBTC is mainly centered in North America, where TB case rates are still falling.
Got something to say?